Xarelto
NICE decisions made on Bayer, Celgene and Boehringer drugs
March 26, 2015Sales and Marketing Bayer, Boehringer, Celgene, NHS, Xarelto, imnovid, jardiance
In final guidance NICE has recommended Bayer’s Xarelto and Boehringer’s Jardiance for NHS funding, but not Celgene’s Imnovid. Bayer’s Xarelto …
New drugs give Bayer record sales
February 26, 2015Sales and Marketing Bayer, Eylea, Radium-223 chloride, Stivarga, Xarelto, adempas, aflibercept, dekkers, german, regorafenib, riociguat, xofigo
Bayer has reported strong financial results for 2014 driven primary by sales of new medicines, although controversy surrounding its anti-clotting …
Bayer launches major new stroke trial
January 27, 2015Research and Development, Sales and Marketing Bayer, Canadian Stroke Prevention Intervention Network, Population Health Research Institute, Xarelto, rivaroxaban, stroke
Bayer is enrolling more than 7,000 people in a trial to test whether its blood-thinning drug Xarelto can successfully prevent …
NICE recommends Bayer heart attack drug
January 26, 2015Sales and Marketing ACS, Bayer, J&J, JJ, NICE, Xarelto, q4, rivaroxaban
NICE has recommended Xarelto in final draft guidance as an option for preventing blood clots in people who have had …
Olysio and Xarelto boost J&J’s Q4
January 21, 2015Sales and Marketing J&J, JJ, Janssen, NICE, Remicade, Velcade, Xarelto, financials, hep C, olysio, q4, quarter four
Johnson & Johnson earned a 10% increase in worldwide sales of its drugs in the last quarter of 2014 compared …
Pfizer/BMS blood thinner gains new licence
August 22, 2014Sales and Marketing BMS, DVT, Eliquis, Pfizer, Pradaxa, Xarelto, blood, warfarin
Pfizer and Bristol-Myers Squibb have been handed a much-needed lift after its new blood thinner Eliquis gained a licence extension …
Xarelto lift for Bayer
March 3, 2014Manufacturing and Production, Sales and Marketing Bayer, Eylea, Stivarga, Xarelto, blood thinner, xofigo
Bayer Group says sales of its blood thinner Xarelto will be higher than it had predicted, with peak annual sales …
Boehringer in hot water over Pradaxa risks
February 19, 2014Sales and Marketing Boehringer, Pradaxa, Xarelto, dabigatran, lawsuit
Boehringer Ingelheim attempted to delay and revise the publication of important drug information surrounding its new anticoagulant Pradaxa. This is …
Bayer ‘disappointed’ with FDA
February 18, 2014Sales and Marketing ACS, Bayer, Xarelto, blood, rivaroxaban
Bayer HealthCare has expressed its dismay after the Food and Drug Administration once again rejected further indications for the company’s …
‘More than 2,000’ US lawsuits for Boehringer
February 14, 2014Sales and Marketing Boehringer, Pradaxa, Xarelto, blood thinner, warfarin
Boehringer Ingelheim is facing more than 2,000 lawsuits in the US over allegations that its stroke prevention pill Pradaxa has …
FDA has Xarelto concerns
July 2, 2013Sales and Marketing Bayer, Boehringer, FDA, Pradaxa, Xarelto
The FDA is unsure about an application to further extend the licence for Janssen and Bayer HealthCare’s blood thinner Xarelto …
Xarelto gets ACS indication
May 29, 2013Sales and Marketing ACS, Bayer, Xarelto
Bayer HealthCare’s bloodthinner Xarelto has expanded its reach in Europe with approval for secondary prevention after an acute coronary syndrome …
German regulator assesses more drugs
April 22, 2013Sales and Marketing AMNOG, Bayer, Germany, Pradaxa, Xarelto
A new raft of drugs which will be subject to potentially stringent cost/benefit analysis in Germany has been announced. The …
Xarelto gets EU nod
March 25, 2013Sales and Marketing Bayer, Xarelto
Bayer HealthCare has been given a boost by the recommendation in Europe of its oral blood thinner Xarelto to prevent …
New AF possibility for Xarelto
March 11, 2013Sales and Marketing Bayer, FDA, Xarelto
Bayer HealthCare is to launch a new trial of its oral blood thinner Xarelto just days after the FDA knocked …
Latest content
FibroFind appoints Lee Borthwick as CEO
